PO.PS01.04 · 人群科学

基于年龄的左位数偏倚对胰腺腺癌治疗的影响

Age-based left-digit bias in the treatment of pancreatic adenocarcinoma

海报缩略图:基于年龄的左位数偏倚对胰腺腺癌治疗的影响
编号 896 展板 9 时间 4/19 02:00–05:00 区域 Section 35 主讲 Qianyun Luo, BS
分会场 Survivorship Research Addressing Cancer Disparities
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Qianyun Luo, Bethel Ozed-Williams, David Brauer, Bryan Trottier, Todd Tuttle, Jane Hui, Eric H. Jensen, Jacob Ankeny, Christopher J. LaRocca, Schelomo Marmor

University of Minnesota, Minneapolis, MN

摘要 Abstract

中文摘要
目的:左位数偏倚(left digit bias),即最左侧数字对决策产生不成比例的影响,可能影响治疗决策和患者结局。本研究考察此类偏倚如何影响胰腺腺癌(PDAC)患者的治疗决策,重点关注79岁与80岁患者之间的差异。 方法:一项使用国家癌症数据库(2004-2020)的回顾性队列研究分析了79岁和80岁的PDAC患者。主要暴露因素为基于年龄的左位数偏倚。所测量的主要结局包括所接受治疗的差异和总生存。统计分析包括卡方检验、多变量分析、Kaplan-Meier生存曲线和Cox比例风险模型。 结果:在5,304例患者中(2,718例79岁,2,586例80岁),79岁患者的化疗使用率(50.3%)高于80岁患者(45.1%)(OR 0.79,95% CI 0.70-0.89,p<0.01)。在手术或放疗方面未发现显著差异。化疗与较低的死亡风险相关(HR 0.85,95% CI 0.79-0.92,p<0.01)。两组间校正后的总生存相似(HR 1.00,95% CI 0.93-1.07,p=0.91)。 结论:在PDAC治疗中观察到左位数偏倚,倾向于对79岁而非80岁患者采用化疗。这凸显了在治疗规划中进行年龄中立决策的必要性,以避免可能影响患者诊疗和结局的偏倚。
查看英文原文 English abstract
Purpose: Left digit bias, where the left-most digit disproportionately influences decision-making, can impact treatment decisions and patient outcomes. This study examines how such bias may affect treatment decisions for patients with pancreatic adenocarcinoma (PDAC), focusing on differences between patients aged 79 and 80. Method: A retrospective cohort study using the National Cancer Database (2004-2020) analyzed patients with PDAC aged 79 and 80. The primary exposure was age-based left-digit bias. The main outcomes measured included differences in treatment received and overall survival. Statistical analyses included chi-square tests, multivariate analysis, Kaplan-Meier survival curves, and Cox proportional hazards models. Results: Among 5,304 patients (2,718 aged 79, 2,586 aged 80), chemotherapy use was higher in 79-year-olds (50.3%) than 80-year-olds (45.1%) (OR 0.79, 95% CI 0.70-0.89, p<0.01). No significant differences were found in surgery or radiation. Chemotherapy was associated with lower mortality risk (HR 0.85, 95% CI 0.79-0.92, p<0.01). Adjusted overall survival was similar between groups (HR 1.00, 95% CI 0.93-1.07, p=0.91). Conclusion: Left digit bias was observed in the treatment of PDAC, with a tendency to favor chemotherapy for patients aged 79 over 80. This highlights the need for age-neutral decision-making in treatment planning to avoid biases that could impact patient care and outcomes.
利益披露 Disclosure
Q. Luo, None.. B. Ozed-Williams, None.. D. Brauer, None.. B. Trottier, None.. T. Tuttle, None.. J. Hui, None.. E. H. Jensen, None.. J. Ankeny, None.. C. J. LaRocca, None.. S. Marmor, None.

← 返回 AACR 2026 检索